A Study Evaluating An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSM and TGW

HIV Prevention Clinical Trial

— PrEP-3D RCT  

Official title:

PrEP-3D RCT: A Randomized Controlled Trial Evaluating An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among Persons Assigned Male at Birth Who Have Sex With Persons Assigned Male at Birth

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05474313
• Other study ID #: 21-35533
• Status: Recruiting
• Phase: N/A
• Start date: April 8, 2022
• Est. completion date: December 2023

Study information

• Verified date: September 2022
• Source: Public Health Foundation Enterprises, Inc.
• Contact: Kenneth Coleman, MA
• Phone: 628-217-7443
• Email: kenneth.coleman[@]sfdph.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The PrEP 3D randomized controlled trial (RCT) will study the effectiveness of the PrEP-3D app compared to standard of care for starting pre-exposure prophylaxis (PrEP), continuing PrEP, and adherence to PrEP.

Description:

The investigators will be testing a pharmacist-led model of PrEP delivery combined with mobile app-based PrEP support developed by the investigator's team to improve PrEP initiation and persistence. Alto Pharmacy is a full-service online pharmacy already using mobile and web apps to communicate with patients, providers, laboratories, and insurers to provide timely medication delivery. Alto can provide PrEP prescriptions, order laboratory tests, and perform clinical referrals through a collaborative practice agreement (CPA) with SFDPH that allows transfer of these responsibilities. The investigators have integrated online tools with Alto Pharmacy's technology platform to create PrEP-3D: Digital Diary and Delivery, combining a tailored online support tool with the personalized service of a community pharmacy and the convenience of medication delivery. By removing the requirement for initiation and quarterly visits with a primary care physician for PrEP, the PrEP-3D model will expand access to PrEP visits (including for persons who choose not to go to their primary care provider for PrEP) and reduce burden on the health care system.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older
• Assigned male at birth who reports sex with persons assigned male at birth
• Willing and able to provide written informed consent
• HIV-uninfected by negative 4th generation HIV test during screening
• Owns a smartphone and has private access to the internet
• Able to understand, read, and speak English or Spanish
• Lives in California
• Self-reported evidence of being at-risk for HIV acquisition, including at least one of

the following in the past 6 months:

• = 1 episode of anal/vaginal sex with a male or transgender female partner;
• Diagnosed with a bacterial sexually transmitted infection (STI).
• Interested in taking daily TDF/FTC or TAF/FTC PrEP
• Willing and able to receive PrEP prescriptions through Alto Pharmacy (e.g., no specific pharmacy required by health plan, such as Kaiser HMO)
• Creatinine clearance >30 mL/min
• No contraindications to TDF/FTC or TAF/FTC use

Exclusion Criteria:

• Repeatedly reactive HIV test at screening or enrollment
• Signs or symptoms of acute HIV infection at screening or enrollment
• Currently enrolled in another HIV intervention study.
• Unable to commit to study participation for the duration of the study
• Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Related Conditions & MeSH terms

• Adherence, Medication
• HIV Prevention
• Risk Reduction

Intervention

Behavioral:
• PrEP-3D package
A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
• Standard of Care
Participants are given local standard of care navigation for initiation of PrEP

Locations

Country	Name	City	State
United States	Alto Pharmacy	San Francisco	California
United States	Bridge HIV, San Francisco Department of Public Health	San Francisco	California

Sponsors (3)

Lead Sponsor	Collaborator
Public Health Foundation Enterprises, Inc.	Alto Pharmacy, San Francisco Department of Public Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of PREP-3D on PREP use	Measurement of PrEP adherence using dried blood spot measurements of tenofovir-diphosphate (TFV-DP) levels greater than or equal to 700 fmol/punch	12 months